Noncompartmentally-based pharmacokinetic modeling

Advanced Drug Delivery Reviews

Volumn 48, Issue 2-3, 2001, Pages 265-300

  Veng Pedersen, Peter ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Convolution; Deconvolution; Disposition decomposition; Linear operators; Linear systems analysis; Mean residence times; Mean transit times; Nonparametric pharmacokinetics; Pharmacokinetic modeling; Pharmacokinetic response mapping

Indexed keywords

CONVOLUTION; DECOMPOSITION; DRUG DOSAGE; SYSTEMS ANALYSIS;

LINEAR SYSTEMS ANALYSIS;

PHARMACOKINETICS;

DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG TRANSPORT; LINEAR SYSTEM; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MEAN RESIDENCE TIME; PRIORITY JOURNAL; REVIEW; SYSTEM ANALYSIS; THEORY;

LINEAR MODELS; PHARMACOKINETICS;

EID: 0035844740     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(01)00119-3     Document Type: Review

References (53)

1. Cobelli C., Toffolo G. Compartmental vs. noncompartmental modeling for two accessible pools. Am. J. Physiol. 247:1984;R488-496.
2. Cutler D.J. Linear systems analysis in pharmacokinetics. J. Pharmacokinet. Biopharm. 6:1978;265-282.
3. Gillespie W.R. Noncompartmental versus compartmental modelling in clinical pharmacokinetics. Clin. Pharmacokinet. 20:1991;253-262.
4. Landaw E.M., DiStefano J.J.d. Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations. Am. J. Physiol. 246:1984;R665-677.
5. Piotrovskii V.K. Model and model-independent methods of describing pharmacokinetics: the advantages, drawbacks and interrelationship]. Antibiot. Med. Biotekhnol. 32:1987;492-497.
6. Strand S.E., Zanzonico P., Johnson T.K. Pharmacokinetic modeling. Med. Phys. 20:1993;515-527.
7. Veng-Pedersen P. System approaches in pharmacokinetics: I. Basic concepts. J. Clin. Pharmacol. 28:1988;1-5.
8. Veng-Pedersen P. System approaches in pharmacokinetics. II. Applications. J. Clin. Pharmacol. 28:1988;97-104.
9. Veng-Pedersen P. Linear and nonlinear system approaches in pharmacokinetics. How much do they have to offer? I. General considerations. J. Pharmacokin. Biopharm. 16:1988;413-472.
10. Veng-Pedersen P. Linear and nonlinear system approaches in pharmacokinetics. How much do they have to offer? II. The response mapping operator (RMO) approach. J. Pharmacokin. Biopharm. 16:1988;543-571.
11. Verotta D. Two constrained deconvolution methods using spline functions. J. Pharmacokinet. Biopharm. 21:1993;609-636.
12. Verotta D. Estimation and model selection in constrained deconvolution. Ann. Biomed. Eng. 21:1993;605-620.
13. Fattinger K.E., Verotta D. A nonparametric subject-specific population method for deconvolution. II. External validation. J. Pharmacokinet. Biopharm. 23:1995;611-634.
14. Fattinger K.E., Verotta D. A nonparametric subject-specific population method for deconvolution. I. Description, internal validation, and real data examples. J. Pharmacokinet. Biopharm. 23:1995;581-610.
15. Veng-Pedersen P. An algorithm and computer program for deconvolution in linear pharmacokinetics [see comments]. J. Pharmacokinet. Biopharm. 8:1980;463-481.
16. Gillespie W.R., Veng-Pedersen P., Gibson T.P. Deconvolution applied to the kinetics of extracorporal drug removal. Haemodialysis of cefsulodin. Eur. J. Clin. Pharmacol. 29:1985;503-509.
17. Gillespie W.R., Veng-Pedersen P. Gastrointestinal bioavailability: determination of in vivo release profiles of solid oral dosage forms by deconvolution. Biopharm. Drug Dispos. 6:1985;351-355.
18. Gillespie W.R., Veng-Pedersen P. A polyexponential deconvolution method. Evaluation of the 'gastrointestinal bioavailability' and mean in vivo dissolution time of some ibuprofen dosage forms. J. Pharmacokin. Biopharm. 13:1985;289-307.
19. Veng Pedersen P. Pharmacokinetic analysis by linear system approach I: cimetidine bioavailability and second peak phenomenon. J. Pharm. Sci. 70:1981;32-38.
20. Cutler D.J. Numerical deconvolution by least squares: use of prescribed input functions. J. Pharmacokinet. Biopharm. 6:1978;227-241.
21. Yu Z., Schwartz J.B., Sugita E.T., Foehl H.C. Five modified numerical deconvolution methods for biopharmaceutics and pharmacokinetics studies. Biopharm. Drug Dispos. 17:1996;521-540.
22. Burm A.G., Haak-van der Lely F., van Kleef J.W., Jacobs C.J., Bovill J.G., Vletter A.A., van den Heuvel R.P., Onkenhout W. Pharmacokinetics of alfentanil after epidural administration. Investigation of systemic absorption kinetics with a stable isotope method. Anesthesiology. 81:1994;308-315.
23. Karlsson M.O., Bredberg U. Bioavailability estimation by semisimultaneous drug administration: a Monte Carlo simulation study. J. Pharmacokinet. Biopharm. 18:1990;103-120.
24. Veng-Pedersen P. Drug absorption evaluation in the presence of changes in clearance: an algorithm and computer program for deconvolution with exact clearance correction. J. Pharmacokin. Biopharm. 8:1987;185-203.
25. Madden F.N., Godfrey K.R., Chappell M.J., Hovorka R., Bates R.A. A comparison of six deconvolution techniques. J. Pharmacokinet. Biopharm. 24:1996;283-299.
26. G. Wahba, A Survey of Some Smoothing Problems and the Methods for Solving Them, Univ. of Winsconsin-Madison Statistics Dept., Report 347, 1980.
27. Craven P., Wahba G. Smoothing noise data with spline functions. Numer. Math. 31:1979;377-403.
28. Paintaud G., Helleday L., Maboundou C.W., Alvan G. Limitations of the maximum entropy principle in devising drug input rate. Eur. J. Clin. Pharmacol. 49:1995;139-143.
29. De Nicolao G., De Nicolao A. WENDEC: a deconvolution program for processing hormone time-series. Comput. Methods Programs Biomed. 47:1995;237-252.
30. Hutchinson M.F., deHoog F.R. Smoothing noise data with spline functions. Numer. Math. 47:1985;99-106.
31. Acuff R.V., Thedford S.S., Hidiroglou N.N., Papas A.M., Odom T.A. Jr. Relative bioavailability of RRR- and all-rac-alpha-tocopheryl acetate in humans: studies using deuterated compounds. Am. J. Clin. Nutr. 60:1994;397-402.
32. Barrish A., Olah T.V., Gatto G.J., Michel K.B., Dobrinska M.R., Gilbert J.D. The use of stable isotope labeling and liquid chromatography/tandem mass spectrometry techniques to study the pharmacokinetics and bioavailability of the antimigraine drug, MK-0462 (rizatriptan) in dogs. Rapid Commun. Mass Spectrom. 10:1996;1033-1037.
33. Bode H., Brendel E., Ahr G., Fuhr U., Harder S., Staib A.H. Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine. Eur. J. Clin. Pharmacol. 50:1996;195-201.
34. Hage K., Buhl K., Fischer C., Knebel N.G. Estimation of the absolute bioavailability of flecainide using stable isotope technique. Eur. J. Clin. Pharmacol. 48:1995;51-55.
35. Richard J., Cardot J.M., Godbillon J. Stable isotope methodology for studying the performance of metoprolol Oros tablets in comparison to conventional and slow release formulations. Eur. J. Drug Metab. Pharmacokinet. 19:1994;375-380.
36. Veng-Pedersen P. Theorems and implications of a model independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. I. Derivations and theoretical analysis. J. Pharmacokinet. Biopharm. 12:1984;627-648.
37. Veng-Pedersen P. Mean time parameters in pharmacokinetics. Definition computation and clinical implications (Part II). Clin. Pharmacokinet. 17:1989;424-440.
38. Veng-Pedersen P. Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part I). Clin. Pharmacokinet. 17:1989;345-366.
39. Aarons L. Mean residence time for drugs subject to reversible metabolism. J. Pharm. Pharmacol. 39:1987;565-567.
40. Bagli M., Suverkrup R., Rao M.L., Bode H. Mean input times of three oral chlorprothixene formulations assessed by an enhanced least-squares deconvolution method. J. Pharm. Sci. 85:1996;434-439.
41. Brockmeier D., von Hattingberg H.M. Mean residence time. Methods Find. Exp. Clin. Pharmacol. 8:1986;309-312.
42. Cheng H., Jusko W.J. Mean residence time of oral drugs undergoing first-pass and linear reversible metabolism. Pharm. Res. 10:1993;8-13.
43. Veng-Pedersen P. A simple method for obtaining the mean residence time of metabolites in the body. J. Pharm. Sci. 75:1986;818-819.
44. Veng-Pedersen P. Stochastic interpretation of linear pharmacokinetics: a linear system analysis approach. J. Pharm. Sci. 80:1991;621-631.
45. Veng-Pedersen P., Gillespie W. Mean residence time in peripheral tissue: a linear disposition parameter useful for evaluating a drug's tissue distribution. J. Pharmacokinet. Biopharm. 12:1984;535-543.
46. Veng-Pedersen P., Gillespie W. The mean residence time of drugs in the systemic circulation. J. Pharm. Sci. 74:1985;791-792.
47. Veng-Pedersen P., Gillespie W.R. Single pass mean residence time in peripheral tissues: a distribution parameter intrinsic to the tissue affinity of a drug. J. Pharm. Sci. 75:1986;1119-1126.
48. Verotta D., Sheiner L.B., Beal S.L. Mean time parameters for generalized physiological flow models (semihomogeneous linear systems). J. Pharmacokinet. Biopharm. 19:1991;319-331.
49. Weiss M. Washout time versus mean residence time. Pharmazie. 43:1988;126-127.
50. Zierler K.L. Occupancy principle: identity with that of mean transit time of tracers in biological systems. Science. 163:1969;491-492.
51. Veng-Pedersen P., Mandema J.W., Danhof M. Biophase equilibration times. J. Pharm. Sci. 80:1991;881-886.
52. Smolen V.F., Schoenwald R.D. Drug-absorption analysis from pharmacological data. I. Method and confirmation exemplified for the mydriatic drug tropicamide. J. Pharm. Sci. 60:1971;96-103.
53. Veng-Pedersen P., Miller R. Relative deconvolution. An explicit method for bioavailability comparison not requiring intravenous administration. Int. J. Clin. Pharmacol. Ther. Toxicol. 25:1987;10-14.